Brentuximab vedotin
- 3 January 2012
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 11 (1), 19-20
- https://doi.org/10.1038/nrd3629
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- CD30-targeted antibody therapyCurrent Opinion in Oncology, 2011
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasNew England Journal of Medicine, 2010
- Antibody–drug conjugates: targeted drug delivery for cancerCurrent Opinion in Chemical Biology, 2010
- Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish StudyJournal of Clinical Oncology, 2007
- Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804Annals of Oncology, 2007
- Elevated Serum Levels of CC Thymus and Activation-Related Chemokine (TARC) in Primary Hodgkin's Disease: Potential for a Prognostic FactorCancer Research, 2005
- cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activityBlood, 2003
- Development of potent monoclonal antibody auristatin conjugates for cancer therapyNature Biotechnology, 2003
- The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.2002